Dashboard
1
Strong Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 18.66%
- Healthy long term growth as Operating profit has grown by an annual rate 11.52%
- Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 74.41
2
Negative results in Jun 25
3
With ROCE of 16.61%, it has a very attractive valuation with a 1.03 Enterprise value to Capital Employed
4
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
JPY 7,135 Million (Micro Cap)
6.00
NA
0.00%
0.59
19.83%
1.32
Revenue and Profits:
Net Sales:
10,694 Million
(Quarterly Results - Jun 2025)
Net Profit:
383 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-68.94%
0%
-68.94%
6 Months
-59.59%
0%
-59.59%
1 Year
15.71%
0%
15.71%
2 Years
64.53%
0%
64.53%
3 Years
-36.12%
0%
-36.12%
4 Years
-36.7%
0%
-36.7%
5 Years
104.47%
0%
104.47%
O'will Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
3.68%
EBIT Growth (5y)
11.52%
EBIT to Interest (avg)
74.41
Debt to EBITDA (avg)
0.65
Net Debt to Equity (avg)
0.37
Sales to Capital Employed (avg)
4.27
Tax Ratio
30.80%
Dividend Payout Ratio
19.62%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
18.66%
ROE (avg)
15.05%
Valuation key factors
Factor
Value
P/E Ratio
6
Industry P/E
Price to Book Value
1.04
EV to EBIT
6.19
EV to EBITDA
5.63
EV to Capital Employed
1.03
EV to Sales
0.18
PEG Ratio
0.18
Dividend Yield
NA
ROCE (Latest)
16.61%
ROE (Latest)
17.89%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
10,693.80
8,700.00
22.92%
Operating Profit (PBDIT) excl Other Income
609.20
109.70
455.33%
Interest
14.60
12.80
14.06%
Exceptional Items
0.00
0.00
Consolidate Net Profit
382.90
168.80
126.84%
Operating Profit Margin (Excl OI)
55.90%
5.20%
5.07%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 22.92% vs -12.18% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 126.84% vs -17.46% in Mar 2025
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
39,156.00
31,775.20
23.23%
Operating Profit (PBDIT) excl Other Income
1,255.80
1,025.30
22.48%
Interest
44.90
11.80
280.51%
Exceptional Items
0.00
0.00
Consolidate Net Profit
916.40
696.00
31.67%
Operating Profit Margin (Excl OI)
29.70%
30.20%
-0.05%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is 23.23% vs 1.66% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is 31.67% vs 15.75% in Mar 2024
About O'will Corp. 
O'will Corp.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






